Are you looking to study how biomarker levels change in blood, tissue, and other biospecimens throughout the course of a disease? Perhaps you’d like to simultaneously understand symptom progression and co-morbidity development? Perhaps look at therapeutic response or survival?
The MT Group has longitudinally collected biospecimens for pharmaceutical R&D from thousands of subjects, regularly achieving a 95%+ retention rate for those enrolled.
Many Studies Are Possible:
- Solid tumors, heme malignancies, inflammatory bowel disease, autoimmune disease, COVID-19, NASH, at-risk, healthy, and other populations
- Blood, plasma, serum, saliva, urine, buccal swabs, and tissue
- Comprehensive clinical metadata including medical history, symptoms and severity, co-morbidities, lifestyle, therapies, outcomes, and demographics
- Collections pre-diagnosis, at diagnosis, on first line therapy, on later therapies, and at relapse
